18 results
8-K
EX-10.1
ARVN
Arvinas Inc
27 Nov 23
Arvinas Announces Oversubscribed $350 Million Private Placement
7:11am
set forth herein or in the engagement letter, dated November 15, 2023, between the Company and BofA Securities, Inc. or in the engagement letter, dated … November 15, 2023, between the Company and Goldman Sachs & Co. LLC (together, the “Engagement Letters”); (2) shall be liable for any improper payment
S-3ASR
EX-1.2
ARVN
Arvinas Inc
7 Nov 23
Automatic shelf registration
5:24pm
to such employee’s employment or independent contractor’s engagement with the Company or actions undertaken while employed or engaged with the Company
8-K
EX-1.1
p28s9 ghsly7rqwhmbv
6 Aug 21
Entry into a Material Definitive Agreement
4:09pm
8-K
EX-10.1
cnclz2
22 Jul 21
Arvinas and Pfizer Announce Global Collaboration to Develop and Commercialize PROTAC® Protein
7:30am
8-K
EX-10.2
zmr1iufp
22 Jul 21
Arvinas and Pfizer Announce Global Collaboration to Develop and Commercialize PROTAC® Protein
7:30am
8-K
EX-1.1
mov7qncjnypb
18 Dec 20
Arvinas, Inc. Announces Pricing of $400 Million Public Offering of Common Stock
6:30am
8-K
EX-1.1
i9svgoibm6lg
12 Nov 19
Arvinas, Inc. Announces Pricing of Public Offering of Common Stock
4:02pm
DEF 14A
5k8bvgs1n0t20 m4z91w
12 Apr 19
Definitive proxy
5:02pm
DRS/A
8m8d u6lmxz1
2 Aug 18
Draft registration statement (amended)
12:00am
DRS
jv7vzgjyef
22 Jun 18
Draft registration statement
12:00am
- Prev
- 1
- Next